Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Non-Hodgkin's Lymphoma

Allogeneic or autologous bone marrow transplantation (BMT) for non-Hodgkin’s lymphoma (NHL): results of a provincial strategy

Bone Marrow Transplantation volume 26, pages 859–864 (2000)Cite this article

Abstract

In 1986, the bone marrow transplant centers in Ontario agreed to a strategy for the treatment of patients with NHL. Suitable patients would undergo autotransplant but be referred for allotransplant if they had persistent marrow involvement or an inadequate marrow/stem cell harvest. Data of all patients were recorded in a database. We reviewed this database to compare these transplant modalities with respect to overall survival, rate of relapse and treatment-related mortality. Between January 1986 and August 1997, 429 patients underwent BMT for NHL – 385 autotransplants and 44 allotransplants. Sixty-eight percent of patients received their transplant for aggressive NHL, while the others had indolent lymphoma. Three-year actuarial survival did not differ between allogeneic and autologous BMT: 71% vs 62%, respectively (P = 0.5330 by log-rank testing). Three-year actuarial rate of relapse was lower after allotransplant than autotransplant: 6% vs 41%, respectively (P = 0.0006 by log-rank testing). Treatment-related mortality was higher after allotransplant than autotransplant: 23% vs6%, respectively (P = 0.001 by χ2 analysis). For further comparison, autotransplant patients were randomly matched 2:1 with the allotransplant patients for age ± 5 years, disease status at BMT, disease histology, and year of BMT. In the matched comparison, survival did not differ (relative risk of death after allotransplant: 0.711 (95% CI: 0.309–1.637)). Relapse rate was significantly lower in the allotransplant group (relative risk of relapse for allotransplant: 0.190 (95% CI: 0.043–0.834)) and treatment-related mortality was not significantly different (relative risk for allotransplant: 1.425 (95% CI: 0.527–3.851)). In conclusion, a review of a provincial strategy for treatment of NHL, shows that survival is not different after allogeneic or autologous BMT, but the rate of relapse is lower after allotransplant. These data support continuing the current provincial strategy. Bone Marrow Transplantation (2000) 26, 859–864.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  1. Blay J, Gomez F, Sebban C et al. The international prognostic index correlates to survival in patients with aggressive lymphoma in relapse: analysis of the PARMA trial Blood 1998 92: 3562–3568

    CAS  PubMed  Google Scholar 

  2. Philip T, Guglielmi C, Hagenbeek A et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma New Engl J Med 1995 333: 1540–1545

    Article  CAS  Google Scholar 

  3. Philip T, Armitage JO, Spitzer G et al. High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin’s lymphoma New Engl J Med 1987 316: 1493–1498

    Article  CAS  Google Scholar 

  4. Vose JM, Armitage JO, Bierman PJ et al. Salvage therapy for relapsed or refractory non-Hodgkin’s lymphoma utilizing autologous bone marrow transplantation Am J Med 1989 87: 285–288

    Article  CAS  Google Scholar 

  5. Kroger N, Hoffknecht M, Hanel M et al. Busulfan, cyclophosphamide and etoposide as high-dose conditioning therapy in patients with malignant lymphoma and prior dose-limiting radiation therapy Bone Marrow Transplant 1998 21: 1171–1175

    Article  CAS  Google Scholar 

  6. Rapoport AP, Lifton R, Constine LS et al. Autotransplantation for relapsed or refractory non-Hodgkin’s lymphoma (NHL): long-term follow-up and analysis of prognostic factors Bone Marrow Transplant 1997 19: 883–890

    Article  CAS  Google Scholar 

  7. Verdonck, LF, Dekker AW, Lokhorst HM et al. Allogeneic versus autologous bone marrow transplantation for refractory and recurrent low-grade non-Hodgkin’s lymphoma Blood 1997 90: 4201–4205

    CAS  PubMed  Google Scholar 

  8. Chopra R, Goldstone AH, Pearce R et al. Autologous versus allogeneic bone marrow transplantation for non-Hodgkin’s lymphoma: a case-controlled analysis of the European Bone Marrow Transplant Group Registry data J Clin Oncol 1992 10: 1690–1695

    Article  CAS  Google Scholar 

  9. Ratanatharathorn V, Uberti J, Chatchada K et al. Prospective comparative trial of autologous versus allogeneic bone marrow transplantation in patients with non-Hodgkin’s lymphoma Blood 1994 84: 1050–1055

    CAS  PubMed  Google Scholar 

  10. Kaplan EL, Meier P . Nonparametric estimation from incomplete observations J Am Stat Assoc 1958 53: 157

    Article  Google Scholar 

  11. Cox DR . Regression models and life tables J Roy Stat Soc 1972 34B: 187

    Google Scholar 

  12. Siff PJ, Dahlberg S, Forman SJ et al. Autologous bone marrow transplantation for patients with relapsed or refractory diffuse aggressive non-Hodgkin’s lymphoma: a value of augmented preparative regimens – a Southwest Oncology Group trial J Clin Oncol 1998 16: 48–55

    Article  Google Scholar 

  13. Caballero MD, Rubio V, Rifon J et al. BEAM chemotherapy followed by autologous stem cell support in lymphoma patients: analysis of efficacy, toxicity and prognostic factors Bone Marrow Transplant 1997 20: 451–458

    Article  CAS  Google Scholar 

  14. Jones RJ, Ambiner RF, Piantadosi S et al. Evidence of a graft-versus lymphoma effect associated with allogeneic bone marrow transplantation Blood 1991 77: 649–653

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University Health Network, Princess Margaret Hospital, University of Toronto, Canada

    AD Schimmer, S Jamal, H Messner, A Keating & J Meharchand

  2. Ottawa General Hospital, University of Ottawa, Canada

    L Huebsch

  3. Hamilton Health Services Corporation, McMaster University, Canada

    I Walker & A Benger

  4. Northeastern Regional Cancer Centre, Sudbury, Ontario, Canada

    S Gluck

  5. London Regional Cancer Centre, University of Western Ontario, Canada

    A Smith

Authors
  1. AD Schimmer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S Jamal
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. H Messner
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A Keating
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. J Meharchand
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. L Huebsch
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. I Walker
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. A Benger
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. S Gluck
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. A Smith
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

for the Ontario BMT Network Ontario Canada

Rights and permissions

Reprints and permissions

About this article

Cite this article

Schimmer, A., Jamal, S., Messner, H. et al. Allogeneic or autologous bone marrow transplantation (BMT) for non-Hodgkin’s lymphoma (NHL): results of a provincial strategy. Bone Marrow Transplant 26, 859–864 (2000). https://doi.org/10.1038/sj.bmt.1702625

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1702625

Keywords

This article is cited by

Search

Advanced search

Quick links